On 22 February, IHH Healthcare Berhad made an announcement that its CEO, Dr Kelvin Loh Chi-Keon, has stepped down from his position. Loh has served as the CEO of IHH for nearly three years, having previously held the role of CEO designate and executive director.
During his time as CEO, Loh has been instrumental in leading the company through a period of growth and transformation. His contributions have helped IHH to maintain its position as a leading provider of healthcare services in Asia and the Middle East.
Despite Loh’s resignation, his legacy at IHH will continue, as he remains a significant stakeholder in the company. Loh currently holds 120,000 units in IHH’s subsidiary, Parkway Life Real Estate Investment Trust.
Also read: Investors Plan to “Buy the Dip” In 2023 Bear Market: Singaporean Retail Investors
Looking forward, IHH is well-positioned to continue its growth trajectory, thanks in part to the solid foundation established by Loh during his tenure as CEO. As one of the largest healthcare providers in the region, IHH is committed to delivering top-quality healthcare services and innovative solutions to patients and customers across Asia and the Middle East.
Dr Kelvin Loh Chi-Keon’s resignation as CEO of IHH Healthcare Berhad marks the end of an era for the company. However, his contributions and leadership during his tenure have helped IHH to achieve significant growth and success. As the company looks ahead to the future, it remains focused on delivering world-class healthcare services and solutions to patients and customers throughout the region.
